Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (отвара нови прозор)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Извор‎: Cancer 2013;119(21):3784-7.

Индекс‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (отвара нови прозор)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (отвара нови прозор)

Chakrabarti S, Varma S, Singh S, Kumari S

Извор‎: Eur J Haematol 1998;60(5):313-4.

Индекс‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (отвара нови прозор)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (отвара нови прозор)

Delaney M, Matthews DC, Gernsheimer TB

Извор‎: Pediatr Blood Cancer 2017;64(12):e26641.

Индекс‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (отвара нови прозор)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (отвара нови прозор)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Извор‎: J Urol 2010;184(3):1152-7.

Индекс‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (отвара нови прозор)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (отвара нови прозор)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Извор‎: Leuk Lymphoma 1995;19(1-2):141-4.

Индекс‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (отвара нови прозор)

Pediatric off-label use of recombinant factor VIIa. (отвара нови прозор)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Извор‎: Pediatrics 2009;123(3):1066-72.

Индекс‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (отвара нови прозор)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (отвара нови прозор)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Извор‎: Indian J Pediatr 2011;78(8):961-8.

Индекс‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (отвара нови прозор)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (отвара нови прозор)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Извор‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Индекс‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (отвара нови прозор)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (отвара нови прозор)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Извор‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Индекс‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (отвара нови прозор)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (отвара нови прозор)

Das P, Carcao M, Hitzler J

Извор‎: Pediatr Blood Cancer 2006;47(2):206-9.

Индекс‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (отвара нови прозор)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (отвара нови прозор)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Извор‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Индекс‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (отвара нови прозор)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (отвара нови прозор)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Извор‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Индекс‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (отвара нови прозор)

Off-label use of recombinant factor VIIa in pediatric patients. (отвара нови прозор)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Извор‎: Pediatrics 2012;129(6):e1533-40.

Индекс‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (отвара нови прозор)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (отвара нови прозор)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Извор‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Индекс‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (отвара нови прозор)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (отвара нови прозор)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Извор‎: Med Oncol 2010;27(1):16-9.

Индекс‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (отвара нови прозор)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (отвара нови прозор)

Ucar C, Caliskan U

Извор‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Индекс‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (отвара нови прозор)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (отвара нови прозор)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Извор‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Индекс‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (отвара нови прозор)

The use of DDAVP in children with bleeding disorders. (отвара нови прозор)

Ben-Ami T, Revel-Vilk S

Извор‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Индекс‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (отвара нови прозор)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (отвара нови прозор)

Kobrinsky NL, Tulloch H

Извор‎: J Pediatr 1988;112(6):993-6.

Индекс‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (отвара нови прозор)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (отвара нови прозор)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Извор‎: J Pediatr Surg 2013;48(3):689-94.

Индекс‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (отвара нови прозор)